CASP3 and chronic myelogenous leukemia, BCR-ABL1 positive: Consistent with the above results in Figure 4A,B, MTT and Caspase-3 activity assays demonstrated imatinib resistant CML cell lines were more sensitive to glycolysis inhibitors compared with imatinib sensitive cells (Figure 4C–F), indicating the combination of glycolysis inhibitor with imatinib might display a synergistically inhibitory effect on CML cell lines.